Core Viewpoint - Acadia Pharmaceuticals is anticipated to report a year-over-year decline in earnings despite an increase in revenues for the quarter ended June 2025, with the actual results being crucial for its near-term stock price movement [1][2]. Financial Expectations - The consensus estimate for Acadia's quarterly earnings is $0.14 per share, reflecting a year-over-year decrease of 30%. Revenues are projected to be $260.28 million, representing a 7.6% increase from the previous year [3]. - The consensus EPS estimate has been revised down by 1.59% over the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Potential - Acadia's Most Accurate Estimate is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +17.43%, suggesting a bullish outlook from analysts [12]. - The stock holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Acadia was expected to post earnings of $0.10 per share but exceeded this with earnings of $0.11, achieving a surprise of +10.00% [13]. - Over the past four quarters, Acadia has surpassed consensus EPS estimates three times [14]. Industry Context - In the Zacks Medical - Biomedical and Genetics industry, TG Therapeutics is expected to report earnings of $0.32 per share for the same quarter, indicating a year-over-year increase of 700%, with revenues projected at $136.04 million, up 85.2% from the previous year [18][19].

The market expects Arcutis Biotherapeutics, Inc. (ARQT) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on August 6, might help the stock move higher if these key n ...

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. This company is expected to post quarterly earnings of $0.10 per share in its upcoming report, which represents a year-over-year change of +42.9%. Revenues are expected to be $103.56 million, up 11% from the year-ago quarter. The market expects Certa ...

Core Viewpoint - Capri Holdings (CPRI) is expected to report a year-over-year increase in earnings despite lower revenues for the quarter ended June 2025, with the consensus outlook being crucial for assessing the company's earnings picture [1][3]. Earnings Expectations - The upcoming earnings report is anticipated to show earnings of $0.13 per share, reflecting a significant year-over-year increase of +225%, while revenues are projected to decline by 27.4% to $774.5 million [3]. - The stock price may rise if the actual earnings exceed expectations, whereas a miss could lead to a decline in stock value [2]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised down by 3.54%, indicating a collective reassessment by analysts regarding the company's earnings prospects [4]. - The Most Accurate Estimate for Capri Holdings is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -6.49%, suggesting a bearish outlook from analysts [12]. Historical Performance - Capri Holdings has not been able to beat consensus EPS estimates in the last four quarters, with a notable surprise of -2,962.50% in the last reported quarter where a loss of $0.16 per share was expected, but the actual loss was -$4.90 [13][14]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a favorable Zacks Rank [10]. - Capri Holdings currently holds a Zacks Rank of 5 (Strong Sell), which complicates the prediction of an earnings beat [12]. Conclusion - Capri Holdings does not appear to be a compelling candidate for an earnings beat, and investors should consider other factors when making decisions regarding the stock ahead of the earnings release [17].

Chord Energy Corporation (CHRD) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The earnings report, which is expected to be released on August 6, might help the stock move higher if these key numbers are better th ...

Core Viewpoint - The market anticipates Mirum Pharmaceuticals, Inc. (MIRM) will report a year-over-year increase in earnings driven by higher revenues for the quarter ended June 2025, with actual results being crucial for stock price movement [1][2]. Financial Expectations - The consensus estimate indicates a quarterly loss of $0.31 per share, reflecting a year-over-year improvement of +40.4%. Revenues are projected to reach $108.4 million, representing a 39.2% increase from the same quarter last year [3]. - The consensus EPS estimate has been revised 6.92% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Potential - The Most Accurate Estimate for Mirum Pharmaceuticals is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +8.65%, suggesting a strong likelihood of beating the consensus EPS estimate [12]. - Historical performance shows that Mirum Pharmaceuticals has beaten consensus EPS estimates in two out of the last four quarters, with a notable surprise of +23.08% in the last reported quarter [13][14]. Industry Context - In the Zacks Medical - Biomedical and Genetics industry, Tango Therapeutics, Inc. (TNGX) is expected to report a loss of $0.35 per share for the same quarter, indicating a year-over-year decline of -45.8%. Revenue expectations for Tango are $6.19 million, down 68.9% from the previous year [18][19]. - Tango Therapeutics has a Zacks Rank of 2 (Buy) and an Earnings ESP of +0.57%, suggesting a likelihood of surpassing the consensus EPS estimate [20].

The market expects Watts Water (WTS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates. The earnings report, which is expected to be released on August 6, might help the stock move higher if these key numbers are better t ...

Wall Street expects a year-over-year decline in earnings on higher revenues when MannKind (MNKD) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may m ...

The earnings report, which is expected to be released on August 6, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise. Zacks Consensus Estimate This maker of analysis and pro ...

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Duolingo, Inc. due to higher revenues, with a focus on how actual results compare to estimates impacting stock price [1][2]. Earnings Expectations - The upcoming earnings report is expected to show quarterly earnings of $0.55 per share, reflecting a +7.8% change year-over-year, and revenues of $240.54 million, which is a 34.9% increase from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised 0.71% lower in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Duolingo is lower than the consensus estimate, resulting in an Earnings ESP of -1.52%, suggesting bearish sentiment among analysts [12]. Historical Performance - Duolingo has beaten consensus EPS estimates three out of the last four quarters, with a notable surprise of +38.46% in the last reported quarter [13][14]. Investment Considerations - Despite the potential for an earnings beat, the combination of a negative Earnings ESP and a Zacks Rank of 4 makes it challenging to predict a positive outcome for Duolingo [12][17].